AMEX · CHRO
Healthcare · Biotechnology
$1.35
Up+$0.09 (+7.14%)
Updated Sep 11, 2026, 12:40 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CHRO does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning CHRO.
CHRO research
Company profile and research snapshot.
Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 18, 2024 | Alliance Global Partners | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · May 1, 2025
Channel Therapeutics, a biotechnology company focused on developing non-opioid pain treatments, announced that its 2024 audited financial statements contained a going concern emphasis of matter paragraph, as required by NYSE American listing rules.
GlobeNewswire Inc. · Apr 17, 2025
Ligand Pharmaceuticals and Channel Therapeutics announced a merger agreement, where Ligand's Pelthos Therapeutics subsidiary will be combined with Channel. The combined company will focus on commercializing Pelthos' FDA-approved ZELSUVMI for the treatment of Molluscum contagiosum infections.
GlobeNewswire Inc. · May 13, 2024
FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its CEO Frank Knuettel, will be presenting at Alliance Global Partners Healthcare Company Showcase on Tuesday, May 21, 2024.
GlobeNewswire Inc. · Apr 9, 2024
FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its Chief Executive Officer, Frank Knuettel, has issued the following letter to stockholders:
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CHRO.
No results
No recent SID articles mention CHRO.
